Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Why Organogenesis Holdings Stock Is Soaring Today

By Prosper Junior Bakiny - Jan 14, 2021 at 12:52PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company announced its preliminary fourth-quarter financial results.

What happened?

Shares of regenerative medicine company Organogenesis Holdings ( ORGO -1.91% ) are skyrocketing on Thursday on high trading volume following two pieces of good news the drugmaker announced in the past 24 hours. Organogenesis Holdings' stock is up by 37.9% as of 12:34 p.m. EST after rising by as much as 43.2% today. 

So what

On Wednesday evening Organogenesis Holdings announced preliminary results for its fourth quarter of fiscal 2020. The company said it expects its net revenue to come in between $104.6 million and $106 million, which would represent a 40%-to-42% year-over-year increase. On average, analysts predicted that the drugmaker's revenue for the fourth quarter would be $80.84 million. For the 12-month period that ended on Dec. 31, Organogenesis Holdings thinks it will record net revenue between $336.1 million and $337.5 million, an increase of roughly 29% compared to fiscal 2019.

Letter blocks spelling "bullish."

Image source: Getty Images.

The company expects to report positive GAAP net income and positive adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) for fiscal 2020, something it was unable to do in 2019. Further, on Thursday morning, Organogenesis Holdings announced that it has enrolled the first patient for its phase 3 clinical trial for ReNu for the management of symptoms associated with knee osteoarthritis (OA). OA affects more than 30 million Americans, and the healthcare company sees a major market opportunity ahead if ReNu goes on to earn regulatory approval.

Now what

With these positive developments under its belt, it's not surprising that investors are bidding up shares of Organogenesis Holdings today. And the company could continue to record nice gains once it releases its full fiscal fourth-quarter 2020 results. 

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Organogenesis Inc. Stock Quote
Organogenesis Inc.
$9.76 (-1.91%) $0.19

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/30/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.